title: Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome.
abstract: Cutaneous manifestations of antiretroviral medications for HIV are common and potentially dangerous conditions encountered by dermatologists. Part II of this two-part series on the cutaneous effects of antiretroviral medications for HIV will discuss the four most recent classes of medications that have been developed and immune reconstitution syndrome--an important diagnostic consideration when evaluating a dermatologic patient who is taking antiretroviral medications.
authors.affiliation: Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
authors.forename: Camille E
authors.initials: CE
authors.lastname: Introcaso
authors.forename: Janet M
authors.initials: JM
authors.lastname: Hines
authors.forename: Carrie L
authors.initials: CL
authors.lastname: Kovarik
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D004502:Education, Medical, Continuing; D005260:Female; D005500:Follow-Up Studies; D023581:HIV Fusion Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000139:chemically induced* / Q000453:epidemiology / Q000503:physiopathology; D015994:Incidence; D008297:Male; D018570:Risk Assessment
chemical_list: D023581:HIV Fusion Inhibitors; D019428:HIV Integrase Inhibitors